Eosinophilic Fasciitis Triggered by Nivolumab: A Remarkable Efficacy of the mTOR Inhibitor Sirolimus

Erwan Le Tallec (1) , Alain Lescoat (1, 2) , Alice Ballerie (1) , Berengere Cador (1) , Hervé Lena (1, 3) , Charles Ricordel (1, 3) , Damien Sene (4) , Celeste Lebbe (4, 5) , Patrick Jégo (2) , Nicolas Belhomme (1)

1 CHU Pontchaillou [Rennes]
2 Irset - Institut de recherche en santé, environnement et travail
3 COSS - Chemistry, Oncogenesis, Stress and Signaling
4 Hôpital Cochin [AP-HP]
5 HIPI (UMR_S_976 / U976) - Immunologie humaine, physiopathologie & immunothérapie

The global, randomized, double-blind, phase 3 KEYNOTE-189 study(NCT02578680) showed significantly improved OS and PFS with pembrolizumab(pembro)þpemetrexed (pem)þplatinum compared with placeboþpemþplatinumwith a manageable safety profile in pts with previously untreated metastatic nonsqua-mous NSCLC without targetable EGFR/ALK aberrationsj. We present safety and toler-ability data from Japanese pts enrolled in KEYNOTE-189

Domains: Life Sciences [q-bio]; Cancer

Erwan Le Tallec, Alain Lescoat, Alice Ballerie, Berengere Cador, Hervé Lena, et al.. Eosinophilic Fasciitis Triggered by Nivolumab: A Remarkable Efficacy of the mTOR Inhibitor Sirolimus. Journal of Thoracic Oncology, 2020, 15 (2), pp.E29-E30. ⟨10.1016/j.jtho.2019.09.011⟩. ⟨hal-02470585⟩